CHUGAI PHARMACEUTICAL CO., LTD. Logo

CHUGAI PHARMACEUTICAL CO., LTD.

A research-driven pharmaceutical company developing innovative medical products.

4519 | T

Overview

Corporate Details

ISIN(s):
JP3519400000
LEI:
Country:
Japan
Address:
北区浮間五丁目5番1号

Description

Chugai Pharmaceutical Co., Ltd. is a research and development-driven pharmaceutical company dedicated to creating innovative medical products to address unmet medical needs. As a member of the Roche Group, Chugai leverages its advanced expertise in biotechnology and science to develop novel treatments, establishing a leading position in therapeutic antibodies. The company's strategy emphasizes a shift towards discovery research and early clinical development, the integration of digital technologies, and open innovation through external partnerships. Its core therapeutic areas include oncology, rheumatology, and haemophilia, where it provides biopharmaceuticals and molecular targeted therapies to patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-25 08:42
確認書
Japanese 9.6 KB
2025-07-25 08:40
半期報告書-第115期(2025/01/01-2025/12/31)
Japanese 298.8 KB
2025-04-22 09:07
訂正臨時報告書
Japanese 39.1 KB
2025-03-28 06:43
臨時報告書
Japanese 27.8 KB
2025-03-27 08:12
臨時報告書
Japanese 39.7 KB
2025-03-27 07:57
内部統制報告書-第114期(2024/01/01-2024/12/31)
Japanese 24.8 KB
2025-03-27 07:50
確認書
Japanese 9.6 KB
2025-03-27 07:48
有価証券報告書-第114期(2024/01/01-2024/12/31)
Japanese 3.3 MB
2024-07-26 08:02
確認書
Japanese 9.6 KB
2024-07-26 08:01
半期報告書-第114期(2024/01/01-2024/12/31)
Japanese 330.6 KB
2024-07-26 07:35
確認書
Japanese 9.6 KB
2024-07-26 07:30
訂正有価証券報告書-第113期(2023/01/01-2023/12/31)
Japanese 1.8 MB
2024-04-25 08:09
確認書
Japanese 9.6 KB
2024-04-25 08:07
四半期報告書-第114期第1四半期(2024/01/01-2024/03/31)
Japanese 272.0 KB
2024-04-24 08:21
確認書
Japanese 9.6 KB

Automate Your Workflow. Get a real-time feed of all CHUGAI PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CHUGAI PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CHUGAI PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celltrion, Inc. Logo
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
South Korea
068270
Celltrion Pharm Inc. Logo
Manufactures and supplies chemical pharmaceuticals and biosimilar products.
South Korea
068760
Develops and manufactures medical devices, tissue grafts, and advanced biologics.
South Korea
049180
Celon Pharma S.A. Logo
An integrated pharmaceutical company researching and manufacturing modern drugs.
Poland
CLN
Celularity Inc Logo
Develops allogeneic cell therapies and biomaterials from the human placenta.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Clinical-stage pharmaceutical company developing medicines for unmet medical needs.
United States of America
CNTA
Century Therapeutics, Inc. Logo
Develops iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases.
United States of America
IPSC
Cereno Scientific AB Logo
Clinical-stage biotech developing drugs for rare cardiovascular & pulmonary diseases.
Sweden
CRNO
CERO THERAPEUTICS HOLDINGS, INC. Logo
Immunotherapy company developing engineered T cell therapeutics for cancer treatment.
United States of America
CERO
CERUS CORP Logo
Develops pathogen inactivation technology to reduce transfusion-transmitted infections.
United States of America
CERS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.